Great medicines make great investments, and Casdin Capital invests in all aspects of today’s Life Sciences revolution.
13 letters, 2012 to 2026
AUM: $2.9B · Form ADV, 31 Mar 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: RVMD | Current | Biological Products, (No Diagnostic Substances) | COM | 2,577,333 | 0 | 0.0% | 1.19% | $529M | +$46M | 23.04% | $34.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RLAY | Current | Biological Products, (No Diagnostic Substances) | COM | 16,035,240 | 0 | 0.0% | 7.26% | $289M | -$11M | 12.61% | $3.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| GeneDx Holdings Corp. | Nasdaq: WGS | Current | Services-Health Services | COM CL A | 3,707,164 | 0 | 0.0% | 12.37% | $268M | +$14M | 11.68% | $1.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Biolife Solutions Inc | Current | COM NEW | 4,500,000 | -155,000 | -3.3% | $175M | +$43M | 7.62% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: ILMN | Current | Laboratory Analytical Instruments | COM | 530,000 | 0 | 0.0% | 0.35% | $145M | +$52M | 6.32% | $29.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GRAL | Current | Services-Medical Laboratories | COM | 680,000 | +200,000 | +41.7% | 1.51% | $95M | +$63M | 4.15% | $4.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| 10x Genomics, Inc. | Nasdaq: TXG | Current | Laboratory Analytical Instruments | CL A COM | 1,050,000 | 0 | 0.0% | $95M | +$55M | 4.13% | $7.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LAB | Current | Pharmaceutical Preparations | COM | 88,783,856 | 0 | 0.0% | 22.49% | $66M | -$7M | 2.86% | $242M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Neurogene Inc. | Nasdaq: NGNE | Current | Pharmaceutical Preparations | COM | 1,585,361 | +40,000 | +2.6% | 7.66% | $44M | -$4M | 1.92% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SRRK | Current | Biological Products, (No Diagnostic Substances) | COM | 850,000 | +185,000 | +27.8% | 0.70% | $41M | +$4M | 1.79% | $6.1B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PSNL | Current | Services-Medical Laboratories | COM | 2,300,000 | -250,000 | -9.8% | 2.12% | $37M | +$3M | 1.63% | $1.6B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BEAM | Current | Biological Products, (No Diagnostic Substances) | COM | 1,500,000 | +150,000 | +11.1% | 1.45% | $37M | -$10M | 1.60% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Tempus AI, Inc. | Nasdaq: TEM | Current | Services-Computer Programming, Data Processing, Etc. | CL A | 423,597 | +423,597 | New | $35M | +$35M | 1.51% | $10.9B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SRPT | Current | Pharmaceutical Preparations | COM | 1,820,000 | +1,350,000 | +287.2% | 1.70% | $33M | +$25M | 1.44% | $1.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GH | Current | Services-Medical Laboratories | COM | 185,000 | 0 | 0.0% | 0.14% | $33M | +$5M | 1.44% | $19.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GPCR | Current | Pharmaceutical Preparations | SPONSORED ADS | 1,030,000 | -145,000 | -12.3% | 0.48% | $32M | -$31M | 1.40% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALNY | Current | Pharmaceutical Preparations | COM | 120,000 | +45,000 | +60.0% | 0.09% | $30M | +$7M | 1.29% | $19.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Denali Therapeutics Inc. | Nasdaq: DNLI | Current | Biological Products, (No Diagnostic Substances) | COM | 1,250,000 | -795,000 | -38.9% | 0.78% | $26M | -$27M | 1.13% | $2.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Hims & Hers Health, Inc. | NYSE: HIMS | Current | Services-Offices & Clinics of Doctors of Medicine | COM CL A | 800,000 | +100,000 | +14.3% | $24M | -$0.4M | 1.04% | $3.8B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MAZE | Current | Biological Products, (No Diagnostic Substances) | COM | 843,857 | 0 | 0.0% | 1.54% | $23M | -$2M | 1.00% | $1.8B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SEPN | Current | Pharmaceutical Preparations | COM | 553,268 | 0 | 0.0% | 1.16% | $22M | +$3M | 0.94% | $1.9B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PBLS | Current | Pharmaceutical Preparations | COM | 645,690 | 0 | 0.0% | $21M | +$3M | 0.91% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Adlai Nortye Group Ltd. | Nasdaq: ANL | Current | Pharmaceutical Preparations | SPONSORED ADS | 1,250,000 | 0 | 0.0% | $20M | +$6M | 0.87% | $583M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TSHA | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 3,900,000 | +650,000 | +20.0% | 1.20% | $19M | -$3M | 0.83% | $1.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| AgomAb Therapeutics NV | Nasdaq: AGMB | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 1,550,000 | 0 | 0.0% | $17M | -$3M | 0.75% | $277M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORIC | Current | Pharmaceutical Preparations | COM | 1,250,000 | +1,250,000 | New | 1.20% | $17M | +$17M | 0.73% | $800M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MRNA | Current | Biological Products, (No Diagnostic Substances) | COM | 75,000 | 0 | 0.0% | 0.02% | $14M | +$9M | 0.63% | $80.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: VCYT | Current | Services-Medical Laboratories | COM | 276,308 | 0 | 0.0% | 0.34% | $13M | -$4M | 0.55% | $2.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: DGX | Current | Services-Medical Laboratories | COM | 50,000 | 0 | 0.0% | 0.05% | $12M | +$1M | 0.51% | $28.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BIIB | Current | Biological Products, (No Diagnostic Substances) | COM | 50,000 | +50,000 | New | 0.03% | $11M | +$11M | 0.49% | $36.5B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: EWTX | Current | Pharmaceutical Preparations | COM | 265,000 | +265,000 | New | 0.24% | $11M | +$11M | 0.47% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ABSI | Current | Services-Commercial Physical & Biological Research | COM | 973,260 | 0 | 0.0% | 0.56% | $10M | -$0.8M | 0.46% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PRME | Current | Biological Products, (No Diagnostic Substances) | COM | 3,167,175 | 0 | 0.0% | 1.74% | $10M | -$2M | 0.42% | $856M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BNTX | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 85,000 | +85,000 | New | 0.03% | $8M | +$8M | 0.36% | $20.2B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Braveheart Bio, Inc. | Nasdaq: BRVE | Current | Pharmaceutical Preparations | COM SHS | 400,000 | +400,000 | New | 0.44% | $8M | +$8M | 0.35% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Rapport Therapeutics, Inc. | Nasdaq: RAPP | Current | Pharmaceutical Preparations | COM | 200,000 | +200,000 | New | 0.34% | $7M | +$7M | 0.29% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: NTLA | Current | In Vitro & In Vivo Diagnostic Substances | COM | 355,000 | 0 | 0.0% | 0.25% | $4M | -$2M | 0.19% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Uniqure NV | Current | SHS | 150,000 | 0 | 0.0% | $4M | -$3M | 0.16% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: IPSC | Current | Biological Products, (No Diagnostic Substances) | COM | 1,228,190 | 0 | 0.0% | 0.68% | $2M | -$0.9M | 0.09% | $240M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CTNM | Current | Pharmaceutical Preparations | CL A | 148,333 | 0 | 0.0% | $2M | -$0.4M | 0.09% | $355M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PACB | Current | Laboratory Analytical Instruments | COM | 723,767 | 0 | 0.0% | 0.23% | $2M | +$0.5M | 0.07% | $550M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BBOT | Current | Pharmaceutical Preparations | COM NEW | 282,312 | 0 | 0.0% | 0.35% | $1M | -$1.0M | 0.05% | $149M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: EDIT | Current | Biological Products, (No Diagnostic Substances) | COM | 445,000 | 0 | 0.0% | 0.29% | $1M | -$0.3M | 0.05% | $264M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GLUE | Current | Biological Products, (No Diagnostic Substances) | COM | 86,014 | -100,000 | -53.8% | 0.10% | $1M | -$3M | 0.04% | $761M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Kardigan, Inc. | Nasdaq: KARD | Current | Pharmaceutical Preparations | COM | 50,000 | 0 | 0.0% | 0.05% | $0.7M | -$0.5M | 0.03% | $1.2B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: RXRX | Current | Biological Products, (No Diagnostic Substances) | CL A | 165,323 | 0 | 0.0% | 0.03% | $0.7M | +$0.1M | 0.03% | $1.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: DNA | Current | Biological Products, (No Diagnostic Substances) | CL A NEW | 36,493 | 0 | 0.0% | $0.5M | +$0.1M | 0.02% | $532M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Tenaya Therapeutics, Inc. | Nasdaq: TNYA | Current | Biological Products, (No Diagnostic Substances) | COM | 361,969 | 0 | 0.0% | 0.16% | $0.2M | -$0.0M | 0.01% | $68M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Avidity Biosciences Inc | Exited | COM | 0 | -1,000,000 | -100.0% | -$72M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Verve Therapeutics Inc | Exited | COM | 0 | -4,095,571 | -100.0% | -$46M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Blueprint Medicines Corp | Exited | COM | 0 | -326,378 | -100.0% | -$29M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: SPRY | Exited | Pharmaceutical Preparations | COM | 0 | -1,600,000 | -100.0% | -$19M | $338M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: SION | Exited | Pharmaceutical Preparations | COM | 0 | -400,000 | -100.0% | -$18M | $134M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: CDXS | Exited | Industrial Organic Chemicals | COM | 0 | -7,200,000 | -100.0% | -$18M | $115M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: UNH | Exited | Hospital & Medical Service Plans | COM | 0 | -50,000 | -100.0% | -$17M | $296B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Qiagen NV | Exited | ORD SHARES | 0 | -360,000 | -100.0% | -$14M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: DXCM | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -175,000 | -100.0% | -$12M | $29.9B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: CI | Exited | Hospital & Medical Service Plans | COM | 0 | -40,000 | -100.0% | -$11M | $71.4B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: ONC | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -40,000 | -100.0% | -$11M | $45.7B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| 2seventy Bio Inc | Exited | COMMON STOCK | 0 | -2,000,000 | -100.0% | -$10M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: INCY | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -100,000 | -100.0% | -$10M | $23.6B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: MLTX | Exited | Pharmaceutical Preparations | CLASS A ORD | 0 | -450,000 | -100.0% | -$8M | $939M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: GEHC | Exited | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | COMMON STOCK | 0 | -100,000 | -100.0% | -$8M | $37.0B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Eli Lilly | NYSE: LLY | Exited | Pharmaceutical Preparations | COM | 0 | -8,500 | -100.0% | -$7M | $1.20T | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: FDMT | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,150,000 | -100.0% | -$6M | $604M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Syndax Pharmaceuticals Inc | Nasdaq: SNDX | Exited | Pharmaceutical Preparations | COM | 0 | -650,000 | -100.0% | -$6M | $822M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Nasdaq: FTRE | Exited | Services-Medical Laboratories | COMMON STOCK | 0 | -275,000 | -100.0% | -$5M | $1.9B | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Exact Sciences Corp | Exited | COM | 0 | -90,000 | -100.0% | -$5M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: IRON | Exited | Pharmaceutical Preparations | COM | 0 | -65,000 | -100.0% | -$5M | $3.5B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: LEGN | Exited | Pharmaceutical Preparations | SPONSORED ADS | 0 | -215,000 | -100.0% | -$5M | $3.1B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: VSTM | Exited | Pharmaceutical Preparations | COM NEW | 0 | -600,000 | -100.0% | -$4M | $864M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: AGIO | Exited | Pharmaceutical Preparations | COM | 0 | -100,000 | -100.0% | -$3M | $1.7B | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: SLDB | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -775,000 | -100.0% | -$3M | $719M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: TDOC | Exited | Services-Offices & Clinics of Doctors of Medicine | COM | 0 | -300,000 | -100.0% | -$2M | $1.4B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: DYN | Exited | Pharmaceutical Preparations | COM | 0 | -100,000 | -100.0% | -$1M | $3.0B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Exscientia PLC | Exited | ADS | 0 | -213,900 | -100.0% | -$1M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: TNGX | Exited | Pharmaceutical Preparations | COM | 0 | -125,000 | -100.0% | -$0.2M | $3.8B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Kronos Bio Inc | Exited | COM | 0 | -123,839 | -100.0% | -$0.1M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 |